Hospitals Ask Court to Block 340B Rebate Program
Plaintiffs say federal health officials underestimated costs of the rebate program scheduled to take effect January 1, 2027.
Updated on Nov. 16, 2026 in Healthcare

Live Poll
Should the federal government block hospital drug rebate programs over cost concerns?
The American Hospital Association and other plaintiffs asked the U.S. District Court for the District of Maine to preliminarily block HRSA's 340B rebate program. In a reply brief filed November 16, 2026, they argue the revised program fails the Administrative Procedure Act's reasoned decision-making standard.
Why it matters
The plaintiffs argue the program would impose hundreds of millions of dollars in costs that would push 340B hospitals to cut services, affecting how U.S. hospitals serving low-income patients are funded. The outcome could determine whether the program takes effect as scheduled.
HRSA's only cost estimate is $537 million a year for claims data submissions, assuming five hours of work per week, while an updated IQVIA study put annual interest costs for 10 drugs at $53.7 million, a figure HRSA excluded. The court has not ruled on the injunction request, and HHS has not quantified the program's benefits.
The players
Health Resources and Services Administration (HRSA)
HRSA is the federal agency within the U.S. Department of Health and Human Services that administers the 340B drug pricing program for safety-net providers.
U.S. Department of Health and Human Services (HHS)
HHS is the federal department responsible for health policy and programs, and it is defending the rebate program in court.
American Hospital Association
The American Hospital Association is a national trade group representing hospitals and health systems, and it is a lead plaintiff challenging the rebate program.
The details
The plaintiffs are asking the court to enjoin the rebate program and any approvals of drug companies' applications to participate. They say HHS did not follow the court's December 2025 instruction to fortify the program and that HRSA excluded financing float costs and relied on an outdated version of an IQVIA study.
Timeline
December 2025: Court ruling instructs HHS to fortify the rebate program.
November 16, 2026: Plaintiffs file reply brief seeking to block the program.
January 1, 2027: Rebate program is scheduled to take effect.
Roadmap
The rebate program is a change to the 340B Drug Pricing Program established under Section 340B of the Public Health Service Act, which gives safety-net providers discounted drug prices. The lawsuit tests whether HHS can restructure that long-standing program through a rebate model without meeting federal reasoned decision-making requirements.
If the rebate program takes effect, 340B hospitals may face new costs that could lead to reduced services for patients who rely on discounted medications. The court's ruling on the injunction will determine whether those changes proceed on schedule.
The takeaway
The lawsuit highlights that cost estimates for federal drug programs can be contested when key expenses are excluded, so hospitals and patients should watch how the court weighs HHS's analysis before the January 2027 start date.
What happens next
The District of Maine court is expected to rule on the preliminary injunction motion before the rebate program's scheduled January 1, 2027 start.
Further reading
Explore more healthcare industry news to see how federal drug pricing rules affect hospitals across the United States.
Live Poll
Should the federal government block hospital drug rebate programs over cost concerns?






